BellBrook

SIRT2 (human) (rec.) (His) (active) (100µg)

As low as CHF 782.00
In stock
Only %1 left
BBL-2343-C100100 µgCHF 782.00
NEW
More Information
Product Details
Synonyms Sirtuin2; NAD-dependent Deacetylase Sirtuin-2; SIR2-like protein 2; SIR2L2
Product Type Protein
Properties
Source/Host Insect cells
Sequence

Full-length human SIRT2 (aa 1-389) with a C-terminal His-tag.

Crossreactivity Human
Application

Drug Discovery

Biological Activity

The enzyme has been thoroughly validated with the Transcreener OAADPr Assay Kit. For specific activity, please refer to the Certificate of Analysis for each individual enzyme lot. Currently used with the Transcreener assay at a concentration of 12nM in a 10 μL reaction.

MW 44kDa
Purity ≥90% (SDS-PAGE)
Accession Number Q8IXJ6
Formulation Liquid in 50 mM Tris, 500 mM NaCl, and 5% Glycerol (pH 8.0).
Other Product Data

Click here for Complete Information from the Original Manufacturer
Our product description may differ slightly from the original manufacturer's product datasheet.

Human SIRT2: Q8IXJ6

Shipping and Handling
Shipping DRY ICE
Short Term Storage -20°C
Long Term Storage -80°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability Stable for at least 6 months after receipt when stored at -80°C.
Documents
Product Specification Sheet
Datasheet Download PDF
Description

Sirtuins (Silent information regulators; SIRTs) deacetylate and/or ADP-ribosylate lysine residues of target proteins in an NAD+-dependent manner. Sirtuins are critical regulators of many cellular processes, including insulin secretion, the cell cycle and apoptosis. Sirtuins, in particular SIRT1, emerged as critical regulators of longevity and aging in several model organisms. Furthermore, a variety of age-associated diseases such as type 2 diabetes, obesity, osteoporosis, and Alzheimer’s disease are associated with sirtuins. Sirtuin-2 is a NAD-dependent protein deacetylase, which deacetylates the 'Lys-40' of a-tubulin. It is involved in the control of mitotic exit in the cell cycle. Furthermore, a variety of age-associated diseases such as type 2 diabetes, obesity, osteoporosis, and Alzheimer’s disease are associated with sirtuins. Selective inhibition of Sirtuin-2 achieves neuroprotection and identifies Sirtuin-2 to be a potential therapeutic avenue in Huntington’s and Parkinson’s disease.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.